Document:

Exhibit 10.6

Exhibit 10.6

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND
APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER OF THESE SECURITIES (SUBJECT TO THE PROVISIONS OF ARTICLE 5 BELOW), SUCH
OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.

WARRANT TO PURCHASE STOCK

Company: Biolase Technology, Inc., a Delaware corporation

Number of Shares: As set forth below

Class of Stock: Common Stock, $0.001 par value per share

Warrant Price: As set forth below

Issue Date: May 27, 2010

Expiration Date: May 26, 2015

			
	Credit Facility:	 	This Warrant is issued in connection with that certain
Loan and Security Agreement of even date herewith among
Midcap Financial, LLC, Silicon Valley Bank and the
Company (as amended and in effect from time to time, the
“Loan Agreement”).

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK
(together with any successor or permitted assignee or transferee of this Warrant or of any Shares
issued upon exercise or conversion hereof, “Holder”) is entitled to purchase the number of fully
paid and non-assessable shares (the “Shares”) of the above-stated Class of Stock (the “Class”) of
the above-named company (the “Company”) at the above-stated Warrant Price per Share, all as set
forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and
upon the terms and conditions set forth in this Warrant.

A. Number of Shares; Warrant Price. This Warrant shall be exercisable for the Initial
Shares, plus the Additional Shares (if any).

(1) Initial Shares.

(a) Initial Shares. As used herein, “Initial Shares” means 30,508 shares of the Class,
subject to adjustment from time to time in accordance with the provisions of this Warrant.

(b) Initial Shares Warrant Price. The purchase price per Initial Share (the “Initial
Shares Warrant Price”) shall be $1.77, subject to adjustment from time to time in accordance with
the provisions of this Warrant.

 

 

 

(2) Additional Shares.

(a) Additional Shares. Upon the making by Holder (or its affiliate) of the Term B Loan
(as defined in the Loan Agreement) to the Company under the Loan Agreement, if at all, this Warrant
automatically shall become exercisable for such number of additional shares of the Class (the
“Additional Shares”) as shall equal (a)(i) 0.06, multiplied by (ii) the principal amount of such
Term B Loan made by Holder (or its affiliate), divided by (b) the Additional Shares Warrant Price,
and subject to adjustment thereafter from time to time in accordance with the provisions of this
Warrant.

(b) Additional Shares Warrant Price. The purchase price per Additional Share (the
“Additional Shares Warrant Price”) shall be the average closing price reported for a share of the
Class on the principal US stock exchange or trading market on which shares of the Class are then
traded or quoted for the twenty (20) consecutive trading days immediately preceding the date on
which Holder (or its affiliate) makes the Term B Loan to the Company, subject to adjustment from
time to time thereafter in accordance with the provisions of this Warrant.

(3) As used herein: (a) ”Shares” means the Initial Shares together with the Additional Shares
(if any) for which this Warrant becomes exercisable in accordance with paragraph A(2)(a) above, and
subject to adjustment from time to time in accordance with the provisions of this Warrant; and (b)
“Warrant Price” means the Initial Shares Warrant Price with respect to the Initial Shares, and the
Additional Shares Warrant Price with respect to the Additional Shares; all as adjusted from time to
time in accordance with the provisions of this Warrant.

ARTICLE 1. EXERCISE.

1.1 Method of Exercise. Holder may exercise this Warrant by delivering the original
of this Warrant together with a duly executed Notice of Exercise in substantially the form attached
as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion
right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to
an account designated by the Company), or other form of payment acceptable to the Company for the
aggregate Warrant Price for the Shares being purchased.

1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1,
Holder may from time to time convert this Warrant, in whole or in part, into a number of Shares
determined by dividing (a) the aggregate fair market value of the Shares or other securities
otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares
by (b) the fair market value of one Share. The fair market value of the Shares shall be determined
pursuant to Article 1.3.

1.3 Fair Market Value. If shares of the Class are then publicly listed or quoted on
one or more securities exchanges, inter-dealer quotation systems or over-the-counter markets, the fair market value of a Share shall be the closing price of a share of the
Class reported on the principal such exchange, system or market for the business day immediately
before Holder delivers this Warrant together with its Notice of Exercise to the Company. If
shares of the Class are not then publicly listed or quoted on one or more securities exchanges,
inter-dealer quotation systems or over-the-counter markets, then the Board of Directors of the
Company shall determine the fair market value of a Share in its reasonable good faith judgment.

 

2

 

1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or
converts this Warrant and, if applicable, the Company receives payment of the aggregate Warrant
Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this
Warrant has not been fully exercised or converted and has not expired, a new warrant of like tenor
representing the Shares not so acquired.

1.5 Replacement of Warrants. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss,
theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant,
the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

1.6 Treatment of Warrant Upon Acquisition of Company.

1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale or
other disposition of all or substantially all of the assets of the Company, or any reorganization,
consolidation, merger, or sale of outstanding equity securities of the Company by the holders
thereof, where the holders of the Company’s outstanding voting equity securities as of immediately
before the transaction beneficially own less than a majority of the outstanding voting equity
securities of the surviving or successor entity as of immediately after the transaction.

1.6.2 Treatment of Warrant at Acquisition.

A) Holder agrees that, in the event of an Acquisition in which the sole consideration payable to
the Company and/or its stockholders consists of cash and/or Marketable Securities, this Warrant
shall terminate on and as of the closing of such Acquisition to the extent not previously
exercised. The Company shall provide Holder with written notice of any proposed Acquisition not
later than ten (10) days prior to the closing thereof setting forth the material terms and
conditions thereof.

B) Upon the closing of any Acquisition other than as particularly described in subsection (A)
above, the surviving or successor entity shall assume this Warrant and the obligations of the
Company hereunder, and this Warrant shall, from and after such closing, be exercisable for the same
class, number and kind of securities, cash and other property as would have been paid for or in
respect of the Shares issuable (as of immediately prior to such closing) upon exercise in full
hereof as if such Shares had been issued and outstanding on and as of such closing, at an aggregate
Warrant Price equal to
the aggregate Warrant Price in effect as of immediately prior to such closing; and subject to
further adjustment thereafter from time to time in accordance with the provisions of this Warrant.

 

3

 

C) As used in this Article 1.6, “Marketable Securities” means securities meeting all of the
following requirements: (i) the issuer thereof is then subject to the reporting requirements of
Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and is then current in its filing of all required reports and other information under the
Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that
would be received by Holder in connection with the Acquisition were Holder to exercise or convert
this Warrant on or prior to the closing thereof is then publicly listed or quoted on one or more
securities exchanges, inter-dealer quotation systems or over-the-counter markets, and (iii) Holder
would not be restricted by contract or by applicable federal and state securities laws from
publicly re-selling, within six (6) months and one day following the closing of such Acquisition,
all of the issuer’s shares and/or other securities that would be received by Holder in such
Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of
such Acquisition.

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the
outstanding shares of the Class payable in additional shares of the Class or other securities, then
upon exercise or conversion of this Warrant, for each Share acquired, Holder shall receive, without
cost to Holder, the total number and kind of securities to which Holder would have been entitled
had Holder owned the Shares of record as of the date the dividend occurred. If the Company
subdivides the outstanding shares of the Class by reclassification or otherwise into a greater
number of shares, the number of Shares purchasable hereunder shall be proportionately increased and
the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are
combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the
Warrant Price shall be proportionately increased and the number of Shares shall be proportionately
decreased.

2.2 Reclassification, Exchange, Substitution, Recapitalization or Reorganization.
Upon any reclassification, exchange, substitution, recapitalization or reorganization affecting the
outstanding shares of the Class, Holder shall be entitled to receive, upon exercise or conversion
of this Warrant, the number and kind of securities and property that Holder would have received for
the Shares if this Warrant had been exercised in full immediately before such reclassification,
exchange, substitution, recapitalization or reorganization, at an aggregate Warrant Price not
exceeding the aggregate Warrant Price in effect as of immediately prior thereto. The Company or
its successor shall promptly issue to Holder a certificate pursuant to Article 2.6 hereof setting
forth the number, class and series or other designation of such new securities or other property
issuable upon exercise or conversion of this Warrant as a result of such reclassification,
exchange, substitution, recapitalization or reorganization. The provisions
of this Article 2.2 shall similarly apply to successive reclassifications, exchanges,
substitutions, recapitalizations and reorganizations.

 

4

 

2.3 Adjustment to Warrant Price on Cash Dividend. In the event that the Company at
any time prior or from time to time prior to exercise or conversion in full of this Warrant pays
any cash dividend on the outstanding shares of the Class or makes any cash distribution on or in
respect of the outstanding shares of the Class, and in each such case, the Holder hereof shall,
upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of
the Class receivable thereupon, the amount of cash which such Holder would hold on the date of
such exercise had he been the holder of record of such Class as of the date on which holders of
the Class received or became entitled to receive such cash.

2.4 No Impairment. The Company shall not, by amendment of its Certificate of
Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution,
issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed under this Warrant by the Company,
but shall at all times in good faith assist in carrying out of all the provisions of this Article 2
and in taking all such action as may be necessary or appropriate to protect Holder’s rights under
this Article 2 against impairment.

2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or
conversion of the Warrant and the number of Shares to be issued shall be rounded down to the
nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the
Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount
computed by multiplying the fractional interest by the fair market value of a full Share.

2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class
and/or number of Shares, the Company shall promptly notify Holder in writing, and, at the Company’s
expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief
Financial Officer setting forth such adjustment and the facts upon which such adjustment is based.
The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant
Price, Class and number of Shares in effect upon the date thereof and the series of adjustments
leading to such Warrant Price, Class and number of Shares.

ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

3.1 Representations and Warranties. The Company represents and warrants to, and
agrees with, the Holder as follows:

(a) All Shares which may be issued upon the exercise or conversion of this Warrant shall at
all times during the term hereof and prior to exercise or conversion in full hereof be duly
reserved out of the Company’s authorized and unissued capital stock for issuance upon exercise or
conversion hereof and shall, upon
issuance, be duly and validly issued, fully paid and non-assessable, and free of any liens and
encumbrances except for restrictions on transfer provided for herein or under applicable federal
and state securities laws.

 

5

 

3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any
dividend or distribution upon the outstanding shares of the Class, whether in cash, property,
stock, or other securities and whether or not a regular cash dividend; (b) to offer for
subscription or sale pro rata to the holders of the outstanding shares of the Class any additional
shares of any class or series of the Company’s stock; (c) to effect any reclassification,
reorganization or recapitalization of the shares of the Class; or (d) to effect an Acquisition or
to liquidate, dissolve or wind up; then in each such event the Company shall provide written notice
thereof to Holder thereof at the same time and in the same manner as the Company gives notice
thereof to the holders of the outstanding shares of the Class.

3.3 No Shareholder Rights. Except as provided in this Warrant, Holder will not have
any rights as a shareholder of the Company until the exercise of this Warrant.

ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants
to the Company as follows:

4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon
exercise of this Warrant by Holder will be acquired for investment for Holder’s account, not as a
nominee or agent, and not with a view to the public resale or distribution in violation of
applicable securities laws. Holder also represents that it has not been formed for the specific
purpose of acquiring this Warrant or the Shares.

4.2 Disclosure of Information. Holder has received or has had full access to all the
information it considers necessary or appropriate to make an informed investment decision with
respect to the acquisition of this Warrant and its underlying securities. Holder further has had
an opportunity to ask questions and receive answers from the Company regarding the terms and
conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without
unreasonable effort or expense) necessary to verify any information furnished to Holder or to which
Holder has access.

  4.3 Investment Experience. Holder understands that the purchase of this
Warrant and its underlying securities involves substantial risk. Holder has experience as an
investor in securities of companies in the development stage and acknowledges that Holder can bear
the economic risk of such Holder’s investment in this Warrant and its underlying securities and has
such knowledge and experience in financial or business matters that Holder is capable of evaluating
the merits and risks of its investment in this Warrant and its underlying securities and/or has a
preexisting personal or business relationship with the Company and certain of its officers,
directors or
controlling persons of a nature and duration that enables Holder to be aware of the character,
business acumen and financial circumstances of such persons.

 

6

 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning
of Regulation D promulgated under the Act.

4.5 The Act. Holder understands that this Warrant and the Shares issuable upon
exercise or conversion hereof have not been registered under the Act in reliance upon a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the
Holder’s investment intent as expressed herein. Holder understands that this Warrant and the
Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently
registered under the Act and qualified under applicable state securities laws, or unless exemption
from such registration and qualification are otherwise available.

ARTICLE 5. MISCELLANEOUS.

5.1 Term: This Warrant is exercisable in whole or in part at any time and from time
to time on or before the Expiration Date. 

  5.2 Legends. This Warrant and the Shares shall be imprinted with a legend in
substantially the following form:

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER
SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE
SECURITIES (SUBJECT TO THE PROVISIONS OF ARTICLE 5 OF THAT CERTAIN WARRANT
TO PURCHASE STOCK ISSUED BY THE COMPANY TO SILICON VALLEY BANK DATED AS OF
MAY 27, 2010), SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS
EXEMPT FROM REGISTRATION.

5.3 Compliance with Securities Laws on Transfer. This Warrant and/or the Shares
issued upon exercise or conversion of this Warrant may not be transferred or assigned in whole or
in part without compliance with applicable federal and state securities laws by the transferor and
the transferee (including, without limitation, the delivery of investment representation letters
and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company).
The Company shall not require Holder to provide an opinion of counsel if the transfer is to any
affiliate
of Holder, provided that such affiliate is an “accredited investor” as defined in Regulation D
promulgated under the Act.

 

7

 

5.4 Transfer Procedure. After receipt by Silicon Valley Bank (“Bank”) of the executed
Warrant, Bank will transfer all of this Warrant to SVB Financial Group, Holder’s parent company.
Subject to the provisions of Article 5.3 and upon providing the Company with written notice, SVB
Financial Group and any subsequent Holder may transfer all or part of this Warrant or the Shares
issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon
conversion of the Shares, if any) to any transferee, provided, however, in connection with any such
transfer, SVB Financial Group or such subsequent Holder will give the Company notice of the portion
of the Warrant being transferred with the name, address and taxpayer identification number of the
transferee and Holder will surrender this Warrant to the Company for reissuance to the
transferee(s) (and Holder if applicable). The foregoing provisions of this Article 5.4 shall not
apply to a public sale of any Shares issued on exercise or conversion of this Warrant pursuant to
the provisions of Rule 144 promulgated under the Act.

5.5 Notices. All notices and other communications from the Company to the Holder, or
vice versa, shall be deemed delivered and effective when given personally or mailed by first-class
registered or certified mail, postage prepaid (or on the first business day after transmission by
facsimile), at such address as may have been furnished to the Company or Holder, as the case may
be, in writing by the Company or such holder from time to time. All notices to Holder shall be
addressed as follows until the Company receives notice of a change of address in connection with a
transfer or otherwise:

SVB Financial Group

Attn: Treasury Department

3003 Tasman Drive, HA 200

Santa Clara, CA 95054

Telephone: 408-654-7400

Facsimile: 408-496-2405

Notice to the Company shall be addressed as follows until Holder receives notice of a change
in address:

Biolase Technology, Inc.

Attn: Chief Executive Officer

4 Cromwell

Irvine, CA 92618

Telephone: 949-361-1200

Facsimile: 949-365-4913

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought.

 

8

 

5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the
terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to
collect from the other party all costs incurred in such dispute, including reasonable attorneys’
fees.

5.8 Counterparts. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement.

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of Delaware, without giving effect to its principles regarding conflicts of
law.

“COMPANY”

BIOLASE TECHNOLOGY, INC.

	 	 	 	 	 
	By:

	 	/s/ David M. Mulder
 

Name: David M. Mulder
	 	 
	 

	 	
 

           (Print)
	 	 
	 

	 	Title:  Chief Executive Officer	 	 

“HOLDER”

SILICON VALLEY BANK

	 	 	 	 	 
	By:

	 	/s/ Kurt Miklinksi
 

Name: Kurt Miklinksi
	 	 
	 

	 	
 

           (Print)
	 	 
	 

	 	Title:  Vice President	 	 

 

9Exhibit 10.7

Exhibit 10.7

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of May 27, 2010 by and among
(a) MIDCAP FUNDING III, LLC, a Delaware limited liability company, individually as a Lender, and as
Administrative Agent (“Agent”), and the financial institutions or other entities from time to time
parties as lenders to the Loan Agreement (as defined below), each as a “Lender” and collectively as
“Lenders”), and (b) BIOLASE TECHNOLOGY, INC., a Delaware corporation, (“Grantor”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial
accommodation to Grantor (the “Loans”) in the amounts and manner set forth in that certain Loan and
Security Agreement by and among Lenders, the Agent and Grantor, dated as of May 27, 2010, (as the
same may be amended, modified or supplemented from time to time, the “Loan Agreement”).
Capitalized terms used herein are used as defined in the Loan Agreement. Lenders are willing to
make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to
Agent, for the ratable benefit of the Lenders, and to each Lender a security interest in certain
Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the
obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent, for the ratable
benefit of the Lenders, and to each Lender a security interest in all of Grantor’s right, title and
interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged,
and intending to be legally bound, as collateral security for the prompt and complete payment when
due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and
agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent, for
the ratable benefit of the Lenders, and to each Lender a security interest in all of Grantor’s
right, title and interest in, to and under its intellectual property now owned or hereafter
created, acquired or arising (all of which shall collectively be called the “Intellectual Property
Collateral”), including, without limitation, the following:

1. Any and all copyright rights, copyright applications, copyright registrations and like
protections in each work or authorship and derivative work thereof, whether published or
unpublished and whether or not the same also constitutes a trade secret, now whether now owned or
hereafter acquired, wherever located, including without limitation those set forth on
Exhibit A attached hereto (collectively, the “Copyrights”);

2. Any and all trade secrets, and any and all intellectual property rights in computer
software and computer software products, whether now owned or hereafter acquired, wherever located;

3. Any and all design rights that may be available to Grantor, whether now owned or hereafter
acquired, wherever located;

4. All patents, patent applications and like protections including, without limitation,
improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of
the same, whether now owned or hereafter acquired, wherever located ,including without limitation
the patents and patent applications set forth on Exhibit B attached hereto (collectively,
the “Patents”);

5. Any trademark and servicemark rights, whether registered or not, applications to register
and registrations of the same and like protections, and the entire goodwill of the business of
Grantor connected with and symbolized by such trademarks, whether now owned or hereafter acquired,
wherever located, including without limitation those set forth on Exhibit C attached hereto
(collectively, the “Trademarks”);

 

 

 

6. All mask works or similar rights available for the protection of semiconductor chips,
whether now owned or hereafter acquired, wherever located, including, without limitation those set
forth on Exhibit D attached hereto (collectively, the “Mask Works”);

7. Any and all claims for damages by way of past, present and future infringements of any of
the rights included above, with the right, but not the obligation, to sue for and collect such
damages for said use or infringement of the intellectual property rights identified above;

8. Subject to any counterparty’s interest in such licenses, all licenses or other rights to
use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties
arising from such use to the extent permitted by such license or rights;

9. All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks,
Patents, or Mask Works; and

10. All proceeds and products of the foregoing, including without limitation all payments
under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to the
Agent and the Lenders under the Loan Agreement. The rights and remedies of the Agent and the
Lenders with respect to the security interest granted hereby are in addition to those set forth in
the Loan Agreement and the other Financing Documents, and those which are now or hereafter
available to the Agent and the Lenders as a matter of law or equity. Each right, power and remedy
of the Agent and the Lenders provided for herein or in the Loan Agreement or any of the Financing
Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and
shall be in addition to every right, power or remedy provided for herein and the exercise by the
Agent and the Lenders of any one or more of the rights, powers or remedies provided for in this
Intellectual Property Security Agreement, the Loan Agreement or any of the other Financing
Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or
later exercise by any person, including the Agent or any Lender, of any or all other rights, powers
or remedies.

[Signature page follows.]

 

-2-

 

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to
be duly executed by its officers thereunto duly authorized as of the first date written above.

	 	 	 	 	 	 	 	 	 
	 	 	GRANTOR:	 	 
	 
	 	 	 	 	 	 	 	 
	Address of Grantor:	 	BIOLASE TECHNOLOGY, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	4 Cromwell	 	By:	 	/s/ David M. Mulder	 	 
	 	 	 	 	 	 	 
	Irvine, California 92618

	 	 	 	Title:
	 	Chief Executive Officer	 	 
	Attn: Mr. David M. Mulder, Chief Executive Officer
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	AGENT:	 	 
	 
	 	 	 	 	 	 	 	 
	Address of Agent:	 	MIDCAP FINANCIAL, LLC,

as Agent and as a Lender	 	 
	 
	 	 	 	 	 	 	 	 
	7735 Old Georgetown Road, Suite 400

Bethesda, Maryland 20814
	 	 	 	 	 	 	 	 
	Attn: Portfolio Management – Life Sciences	 	By:	 	/s/ Josh Groman	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]